Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial

Study limitation reported by the research below: “The primary MRD-negative CR analysis is based on the first 420 patients only; the progression-free survival co-primary endpoint is still maturing in the 800-patient confirmatory cohort, so overall clinical benefit is not yet fully established.”